Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Muromonab-CD3 (OKT3, orthoclone)

1

II.a Pulmonary edema, noncardiogenic (NCPE)

1
Last update : 07/09/2012
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

OKT3 (muromonab-CD3) associated hepatitis in a kidney transplant recipient.
Transplantation 2002 Jun 27;73;1957-9 2002 Jun 27
Increased risk of pulmonary edema in diabetic patients undergoing preemptive pancreas transplantation with OKT3 induction.
Transplantation proceedings 1995 Dec;27;3016-7 1995 Dec
A retrospective analysis of the effect of indomethacin on adverse reactions to orthoclone OKT3 in the therapy of acute renal allograft rejection.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1994 Sep;24;486-90 1994 Sep
Cardiopulmonary effects of OKT3: determinants of hypotension, pulmonary edema, and cardiac dysfunction.
Transplantation proceedings 1993 Apr;25;21-4 1993 Apr
General aspects of cytokine-release syndrome: timing and incidence of symptoms.
Transplantation proceedings 1993 Apr;25;16-20 1993 Apr
Acute pulmonary insufficiency due to OKT3 therapy.
Transplantation proceedings 1990 Aug;22;1779-81 1990 Aug
OKT3 and pulmonary capillary permeability.
British medical journal (Clinical research ed.) 1987 Oct 31;295;1099-100 1987 Oct 31

Powered by

  • ^
  • Contact
  • Cookies
  • About